Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Recro Pharma, Inc.

To join this class action, please complete the following Investor Certification.

Recro Pharma, Inc. (NASDAQ: REPH) Investor Certification

Company Name
Plaintiff Certifies That:
The following information is true and correct to the best of my knowledge, information and belief: 1. I have reviewed the Complaint in this action and authorize the filing of this Certification as an exhibit to the Complaint, or any substantively similar complaint or amended complaint to be filed in the future. I retain the law office of Federman & Sherwood, and any other counsel with whom Federman & Sherwood deems appropriate to associate with, to pursue this action on my behalf on a contingency fee basis. 2. If chosen, I am willing to serve as a representative party on behalf of the class (the “Class”), either individually or as part of a group on behalf of the Class as defined in the Complaint, including providing testimony at deposition or trial (if necessary). I am also willing to participate on an executive committee of shareholders.
3. I have made the following transaction(s) during the Class Period in
securities (which are the subject of this action) as follows:
# Shares Purchased Date Of Purchase Price Paid Per Share Class Of Stock (e.g. Common) If Sold, # Of Shares Sold Date Sold (If Sold) Per Share Selling Price
4. I did not purchase these securities at the direction of my attorney or in order to participate in a lawsuit under the Securities Act of 1933 or the Securities Exchange Act of 1934. 5. During the 3-year period preceding the date of this Certification, I have not sought to serve, nor have I served, as a representative to any party or on behalf of any class in any action arising under the Securities Act of 1933 or the Securities Exchange Act of 1934. 6. I will not accept any payment if chosen to serve as a representative party on behalf of the Class beyond my pro rata share of an award to the Class, or as otherwise ordered and approved by the Court, except for such reasonable costs and expenses directly relating to my service as a representative of the Class and as ordered and approved by the Court.
Signed under penalty of perjury, under the laws of the United States of America on:*
MM slash DD slash YYYY
Investor Signature*
Please type: /s/ Your Full Name (e.g. /s/ John Doe)
Print Name*
Type Full Name Here
*
Home Address City State Zip
Home Telephone Number
Cell Telephone Number
Email Address
Secondary Email Address (if any)
By clicking on the button below, I intend to sign and execute this agreement and retain Federman & Sherwood to proceed on Plaintiff’s behalf on a contingency basis.

Oklahoma City, OK (June 4, 2018) – On May 31, 2018, a securities class action lawsuit was filed in the United States District Court for the Eastern District of Pennsylvania against Recro Pharma, Inc. (NASDAQ: REPH). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is July 31, 2017 through May 23, 2018. More specifically, this litigation was filed Defendants made false and/or misleading statements and/or failed to disclose that: (i) IV meloxicam lacked supporting clinical data to show sufficient clinical benefits to receive U.S. Food and Drug Administration (“FDA”) approval; and (ii) as a result, Recro’s public statements were materially false and misleading at all relevant times.

On May 24, 2018, Recro announced that the FDA had declined to approve Recro’s New Drug Application (“NDA”) for IV meloxicam. In its Complete Response Letter, the FDA stated that the drug’s analgesic effects did not meet FDA expectations and raised questions related to chemistry, manufacturing and controls data.

On this news, Recro Pharma’s share price fell $6.79 per share, or 54.7%, to close at $5.63 per share on May 24, 2018, thereby injuring investors.

Plaintiff seeks to recover damages on behalf of all Recro Pharma, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Monday, July 30, 2018 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

If you wish to discuss this action, obtain further information and participate in this or any other securities litigation, or should you have any questions or concerns regarding this notice or preservation of your rights, please contact: Robin Hester at rkh@federmanlaw.com

News & Current Cases

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit against Recro Pharma, Inc.

Recro Pharma, Inc. (NASDAQ: REPH) Investor Certification

Plaintiff Certifies That:

Categories

let’s connect

OKLAHOMA Office

TEXAS Office

# Shares Purchased	Date Of Purchase	Price Paid Per Share	Class Of Stock (e.g. Common)	If Sold, # Of Shares Sold	Date Sold (If Sold)	Per Share Selling Price